August 2026– date –
-
Stem Cell Engineering and Automation Propel Allogeneic Cell Therapy Market Towards $1.97 Billion by 2026
GlobeNewswire (via Report Summary) USA Overview A new market study by Open PR forecasts a robust expansion for the allogeneic cell therapy market, projecting it to reach $1.97 billion by 2026. This significant growth is attributed to adv... -
XellSmart’s iPSC Parkinson’s Therapy XS411 Granted FDA Fast Track Designation, Accelerating Commercialization
Longevity.Technology UK Overview XellSmart's XS411, an allogeneic iPSC-derived cell therapy for Parkinson's disease, has received FDA Fast Track designation. This designation aims to expedite the development and review of therapies for s... -
Capricor Therapeutics’ GMP Facility Now Operational to Support Initial Commercial Launch of Deramiocel for Duchenne Muscular Dystrophy
Capricor Therapeutics USA Overview Capricor Therapeutics reported in its Q2 2026 financial results that its San Diego GMP manufacturing facility is operational to support the initial commercial launch of Deramiocel, an allogeneic cardiac... -
Perfusion Cell Culture Patents 2026: Top 5 Assignees Hold 79.2% Share, Hardware and Cell Line Engineering Dominate Claims
Patsnap Germany Overview A patent analysis based on mid-2026 data reveals that 79.2% of patent activity in perfusion and intensified cell culture technologies is concentrated among the top five assignees. These patents primarily cover ha... -
Commercial-Scale iPSC Cell Therapy: Advancements in Off-the-Shelf Treatments, Immunogenicity, and Cost Reduction are Key
The Medicine Maker UK Overview This article examines the challenges and technological advances in scaling induced pluripotent stem cell (iPSC) platforms for commercial cell therapies. It highlights the shift towards allogeneic, off-the-s... -
VerdaML: AI-Driven ML Framework Optimizes Microalgal Bioreactor Biomass Yield and Lipid Accumulation
Frontiers in Bioengineering and Biotechnology Switzerland Overview The academic paper 'VerdaML' introduces an explainable, dual-objective machine learning framework for optimizing microalgal photobioreactor cultivation. This AI-driven sy... -
Lonza Unveils Rapid Media Prototyping Service (RaMP) to Accelerate Early Biopharmaceutical Development
Lonza Switzerland Overview Lonza launched its Rapid Media Prototyping Service (RaMP), offering biopharmaceutical companies swift access to customized liquid and powder media for accelerated early development. This service provides non-GM... -
Perfusion Bioreactor Adoption Doubles to 65.8% Since 2016, Accelerating Shift to Continuous Biomanufacturing
synbio.intel USA Overview A BioPlan Associates survey from August 2026 reveals that single-use perfusion equipment usage has doubled to 65.8% across all production stages since 2016, indicating an accelerating shift towards continuous bi... -
AI and Digital Twin Technologies Revolutionize Bioprocessing for Sustainable Manufacturing and Enhanced Efficiency
Facebook (CRB) USA Overview Integrating digital twin technology, advanced bioreactor design, and AI is transforming bioprocessing by reducing energy consumption and improving efficiency for sustainable manufacturing. AI accelerates enzym... -
AGC Biologics Secures Multi-Million Dollar Commercial Manufacturing Deal for Yokohama Facility Ahead of 2027 Opening
히트뉴스 (HITNews) South Korea Overview AGC Biologics has signed a multi-year commercial manufacturing contract with an undisclosed global biopharmaceutical company for its new Yokohama facility, reserving approximately half of its mamma...
